Wall Street analyst estimates for Septerna Inc (SEPN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Valuation Ratios
| Price / Book | 4.63 |
| EV / EBITDA | -41.49 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $151000 | $1.1M | $46.0M |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | $151000 | $1.1M | $46.0M |
| Research & Development | $36.0M | $65.3M | $97.6M |
| Selling, General & Admin | $9.7M | $16.6M | $29.2M |
| Operating Expenses | -$1.9M | $81.9M | $126.7M |
| Operating Income | $2.1M | -$80.8M | -$80.8M |
| EBITDA | -$44.7M | -$70.9M | -$47.3M |
| Interest Expense | 0 | 0 | 0 |
| Pre-tax Income | $4.9M | -$72.3M | -$48.9M |
| Income Tax | $691000 | -$498000 | $12000 |
| Net Income | $4.2M | -$71.8M | -$48.9M |
| EPS | $0.03 | $-1.93 | $-1.10 |
| EPS (Diluted) | $0.03 | $-1.93 | $-1.10 |
| Shares Outstanding (Diluted) | $19.5M | $37.2M | $44.3M |
Price
| Price | $38.44 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABUS · BCAX · EYPT · FTRE · KURA · MRVI · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks